Investors and Media
Investor Relations
Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
Arvinas uses their proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.
NASDAQ: ARVN
Price:
Change
Volume
Today's Open
Previous Close
Today's High
Today's Low
52 Week High
52 Week Low
Minimum 15 minutes delayed. Source: LSEG
-
Print Page
-
RSS Feeds
-
Email Alerts
-
Search